Ran Frenkel is EVP & Chief Dev. Officer at Karyopharm Therapeutics Inc. (KPTI). They have made 9 open-market trades across 1 company since 2015, most recently 2022-02-28.
CIK 0001623108
1 open-market purchase totalling $95K since 2015, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KPTI | 169,953 | $10K |
Shares reported on the most recent Form 4, priced at the 2022-03-02 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KPTI | SELL | 2022-02-28 | 2022-03-02 | $10.24 | $17K | -3.8% | +27.3% | -0.8% |
| KPTI | SELL | 2022-02-17 | 2022-02-22 | $12.12 | $35K | -43.1% | -25.2% | -43.9% |
| KPTI | SELL | 2022-02-07 | 2022-02-09 | $9.86 | $20K | +19.2% | -26.7% | -32.8% |
| KPTI | SELL | 2021-02-18 | 2021-02-22 | $14.83 | $43K | -21.1% | -29.9% | -36.9% |
| KPTI | SELL | 2021-02-11 | 2021-02-17 | $15.52 | $32K | -8.0% | -19.3% | -37.5% |
| KPTI | SELL · 10b5-1 | 2020-05-07 | 2020-05-11 | $20.00 | $39K | -7.8% | -15.2% | -26.6% |
| KPTI | SELL | 2020-02-19 | 2020-02-21 | $16.48 | $49K | +70.1% | +16.9% | +22.2% |
| KPTI | SELL | 2017-11-07 | 2017-11-09 | $11.25 | $112K | +3.4% | -1.9% | +22.4% |
| KPTI | SELL | 2016-11-14 | 2016-11-15 | $10.06 | $33K | -4.1% | -0.2% | +4.4% |
| KPTI | BUY | 2015-04-06 | 2015-04-08 | $31.81 | $95K | -46.9% | +3.0% | +3.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.